During a live event, Nizar M. Tannir, MD and participants discussed their takeaways from trial data on recurrent RCC ...

Zanzalintinib and atezolizumab improved overall survival in metastatic colorectal cancer compared to regorafenib, with a median OS of 10.9 vs 9.4 months. The combination showed progression-free ...

Telisotuzumab adizutecan shows promising antitumor activity in advanced pancreatic cancer, with manageable safety and significant clinical benefits in a phase 1 study.

Enfortumab vedotin plus pembrolizumab improved EFS, OS, and pCR rates in MIBC patients ineligible for cisplatin-based chemotherapy. The combination therapy showed a median EFS and OS that were not ...

Dato-DXd showed a 43% reduction in disease progression risk and a 21% reduction in death risk compared to chemotherapy in TNBC patients ineligible for immunotherapy. The TROPION-Breast02 trial ...

R-DXd showed a 50.5% objective response rate in platinum-resistant ovarian cancer, with a 5.6 mg/kg dose deemed optimal for further study. The safety profile was manageable, with 93.5% experiencing ...

Adding apalutamide (Erleada) to androgen deprivation therapy (ADT) in patients with biochemically recurrent prostate cancer reduced the risk of developing metastases and castration-resistant disease, ...

Patients in cohort 9 received enfortumab vedotin at 1.25 mg/kg intravenously on days 1 and 8 plus pembrolizumab at 200 mg intravenously on day 1 of each 21-day cycle. Treatment was administered until ...

An expert discusses the successful long-term use of amivantamab in frontline regimens like MARIPOSA, emphasizing the ...

Targeted Therapies in Oncology | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine ...